Prediction of response to pemetrexed in non-small-cell lung cancer with immunohistochemical phenotyping based on gene expression profiles

BACKGROUND: Palliative pemetrexed-based chemotherapy remains a standard of care treatment for the majority of patients with advanced non-squamous non-small-cell lung cancer (NSCLC). Currently, no predictive markers for pemetrexed treatment are available. METHODS: Resected tumour samples from pemetre...

Descripción completa

Detalles Bibliográficos
Autores principales: Visser, S., Hou, J., Bezemer, K., de Vogel, L. L., Hegmans, J. P. J. J., Stricker, B. H., Philipsen, S., Aerts, J. G. J. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515672/
https://www.ncbi.nlm.nih.gov/pubmed/31088547
http://dx.doi.org/10.1186/s12885-019-5645-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515672/
https://www.ncbi.nlm.nih.gov/pubmed/31088547
http://dx.doi.org/10.1186/s12885-019-5645-x

Ejemplares similares